Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HS-10502 + nab-paclitaxel
- Development stage
- Phase 1
- Lead developer
- Hansoh Pharmaceutical Group
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Oral, Intravenous
01
Overview
HS-10502 + nab-paclitaxel is an investigational combination therapy currently in phase I clinical development for the treatment of advanced solid tumors. HS-10502 is a potent, selective inhibitor of poly(ADP-ribose) polymerase 1 (PARP1), designed to exploit synthetic lethality in tumors with homologous recombination deficiencies. Nab-paclitaxel (nanoparticle albumin-bound paclitaxel, marketed as Abraxane) is an antimicrotubule agent formulated to facilitate paclitaxel delivery and improve tolerability. The rationale for the combination is based on the potential synergy of PARP inhibition with microtubule-disrupting chemotherapy, aiming to enhance tumor cell kill in a variety of solid tumor settings, including ovarian, breast (HER2-negative and triple-negative), prostate, gastric, and peritoneal cancers[5][9].
- Other names
- nanoparticle albumin-bound paclitaxelprotein-bound paclitaxel
02
Targets
PARP1 (Poly (adp-ribose) polymerase 1)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on HS-10502 + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HS-10502 + nab-paclitaxel.